NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN

    公开(公告)号:US20240229036A9

    公开(公告)日:2024-07-11

    申请号:US18278498

    申请日:2022-02-21

    Abstract: A method of inhibiting the function of myostatin is provided.
    An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target sequence in exon 3 of the myostatin gene and is capable of allowing the expression of a splicing variant of myostatin. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and/or hypertrophy, an agent for increasing muscle mass and/or suppressing muscle weakness, an agent for switching the splicing of the myostatin gene from production of myostatin to production of a splicing variant thereof, an agent for decreasing myostatin signaling, and an anticancer agent, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.

    BEARING LUBRICANT COMPOSITION
    3.
    发明申请
    BEARING LUBRICANT COMPOSITION 有权
    轴承润滑剂组合物

    公开(公告)号:US20130096042A1

    公开(公告)日:2013-04-18

    申请号:US13631096

    申请日:2012-09-28

    Inventor: Akihiro ODA

    Abstract: A bearing lubricant composition includes a base oil containing an ester compound (α) represent by the general formula (1), and has a pour point of −30° C. or lower and a viscosity index of 150 or more. [wherein, A1 is a C3-8 linear or branched alkylene group; and at least one of Xa and Xb is a C2-20 linear or branched alkyl ether group, or when it is not an alkyl ether group, it is a C5-13 linear or branched alkyl group.]

    Abstract translation: 轴承润滑剂组合物包含含有由通式(1)表示的酯化合物(α)的基油,其倾点为-30℃以下,粘度指数为150以上。 [其中,A1为C3-8直链或支链亚烷基; 并且Xa和Xb中的至少一个是C2-20直链或支链烷基醚基团,或者当其不是烷基醚基团时,它是C5-13直链或支链烷基。

    Production of highly fat-soluble phosphoramidite

    公开(公告)号:US11891412B2

    公开(公告)日:2024-02-06

    申请号:US16958100

    申请日:2018-12-26

    CPC classification number: C07H21/04

    Abstract: The purpose of the present invention is to provide a method for purifying and preparing a highly liposoluble phosphoramidite, as well as a capping reaction using the highly liposoluble phosphoramidite compound, and as well as a method for preparing oligonucleotide by a liquid phase process using a pseudo solid phase protecting group said method comprising the capping reaction step. The present invention also provides a method for preparing a compound represented by formula (I) [wherein, R1, R2 and R3 are defined as described in the Detailed Description], which comprises the following steps: (1) reacting an aliphatic alcohol and a trivalent phosphorus compound in organic solvent in the presence of an activator or an organic base; (2) washing the resulting reaction mixture with water in a reparatory funnel; (3) recovering the organic layer after the step (2) and concentrating it (with the proviso that the organic solvent used in the step (1) is a nitrile solvent, the steps (2) to (3) may be omitted); (4) solubilizing the resulting residue obtained in the step (3) in an aliphatic hydrocarbon solvent (with the proviso that the organic solvent used in the step (1) is an aliphatic hydrocarbon solvent, the steps (2) to (3) may be omitted); (5) washing the aliphatic hydrocarbon solution prepared in the step (4) with a nitrile solvent in a separatory funnel; (6) recovering the aliphatic hydrocarbon solution after the step (5) to obtain a solution of a phosphoramidite compound. Also the present invention provides also a solution containing highly liposoluble phosphoramidite compound obtained by the preparation method, a capping reagent comprising the same solution and optionally an additive, a capping reaction using the same capping reagent, as well as a method for preparing (oligo)nucleotide by using the pseudo solid phase protecting group, said method comprising the capping reaction step.

Patent Agency Ranking